[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].
The patient was a 71-year-old man. Chemotherapy was conducted in two courses combining TS-1 (120 mg) and CDDP (80 mg) under the diagnosis of AFP-producing gastric cancer with multiple liver metastasis and peritoneal dissemination. Peritoneal dissemination disappeared, liver metastasis almost disappeared after completion of two courses, and the therapeutic efficacy was rated as PR. Then, the patient underwent distal gastrectomy and lymph node dissection. He received TS-1 monotherapy after surgery, but his condition gradually became worse. TS-1 and CDDP combination were given again, but an ileus resulted due to peritonitis carcinomatous. We therefore administered bi-weekly paclitaxel (80 mg/m(2)) intravenously. The ileus disappeared after one week, liver metastatic lesions and ascites were improved after completion of one course, and therapeutic efficacy was rated as PR. Grade 3 neutropenia and grade 1 alopecia occurred, but no other adverse reaction occurred. This therapy made it possible to eat foods, conduct chemotherapy safely while ambulatory. Paclitaxel can be expected to show good therapeutic efficacy and improve QOL of a peritonitis carcinomatosa patient with TS-1 resistant advanced gastric cancer.
Hirashima
Yoshinori
Y
Third Dept. of Internal Medicine, Oita University Hospital.
Kitajima
Kazuaki
K
Sugi
Saori
S
Kagawa
Koichi
K
Kumamoto
Toshihide
T
Murakami
Kazunari
K
Fujioka
Toshio
T
Noguchi
Tsuyoshi
T
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005743:Gastrectomy; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary*; D008197:Lymph Node Excision; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage / Q000494:pharmacology; D017239:Paclitaxel / Q000008:administration & dosage*; D010534:Peritoneal Neoplasms / Q000556:secondary*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000494:pharmacology; D000509:alpha-Fetoproteins / Q000096:biosynthesis
D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; D000509:alpha-Fetoproteins; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel